Is artemisinin resistance already a reality?
The control of malarial disease by drug treatment is at a critical stage. The old therapies such as chloroquine and antifolates have largely failed and we are increasingly dependent upon artemisinin combination therapies (ACTs). Some scientists have questioned whether resistance to arte misinin would ever arise. Recently, however, reports of reduced susceptibility to artemisinin derivatives, such as artesunate, artemether and dihydroartemisin, are accu mu lating from Thailand and Cambodia. The continued emer gence of artemisinin resistance would represent a grave risk to public health.
Arjen Dondorp (Mahidol University, Bangkok, Thailand) described recent data comparing two different artesunate therapies in Pailin (in western Cambodia) and Wang Pha (on the northwestern ThailandMyanmar border). He reported significantly longer parasite clearance times in Pailin for both treatments relative to Wang Pha. There were no significant differences between measured drug levels in vivo in the two areas, and no relationship between these measures and parasite clearance in individuals. Conventional in vitro tests appeared to be insufficiently sensitive to fully identify the artesunateresistance phenotype. No molecular markers for resistance were identified. Dondorp interpreted these data as clearly establishing the presence of artemisinin resistance in Western Cambodia. Chansuda Wongsrichanalai (USAID, Bangkok, Thailand) outlined the work of National Malaria Control Programs in six countries of the Greater Mekong Subregion, where multidrug resistance foci exist. She explained how endemic foci along national borders and migrant popula tions might obstruct elimination policies and how ampli fication of the mdr1 gene for multidrug resistance is believed to play a major role in a loss of artesunatemefloquine efficacy in that region.
Steffen Boormann (University of Heidelberg, Germany) described surveillance for ACT resistance in East Africa These studies present valuable and hardwon data suggesting that the evolution of artemisinin resistance may already be under way, although the question arises of whether these changes represent selection of preexisting response variability or the occurrence of novel mutations. Recurrent themes of the meeting included an emphasis on the crucial importance of measuring both in vivo and in vitro resistance traits which was captured succinctly by XinZhuan Su (National Institutes of Health, Bethesda, USA) in his phrase 'phenotype, phenotype, phenotype'. Another theme emphasized by several speakers was the importance of building a panel of molecular markers of resistance and their use in surveillance and resistance management.
Genetic markers for artemisinin resistance
Rachel Hallett (London School of Hygiene and Tropical Medicine, UK) and Shannon Takala (University of Mary land Medical School, Baltimore, USA) explained how candidate markers will be integrated into two collaborative projects for surveying artemisinin resistance in the field. Hallett described the structure of the MALACTRES consor tium, a European Unionfunded initiative that aims to investigate resistance to artemisinin combination therapy in Nigeria, Burkina Faso and Tanzania. One aim is to sequence candidate genetic markers such as mdr1, atp6 and ubp1 in Plasmodium falciparum parasites not cleared by ACTs, and to evaluate how they contribute to gameto cyte carriage and mosquito infectivity in the presence of the drug.
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Malaria genomics meets drug-resistance phenotyping in the field
The ARC3 project is a Gates Foundationfunded study of potential artesunate resistance in western Cambodia, north western Thailand and Bangladesh. Takala explained how it will track possible pathways of migration of resistant parasites from Cambodia. The molecularmarker/genomic module of ARC3 will use candidategene and genomewide approaches, exploiting wholegenome resequencing and micro array analysis of single nucleotide polymorphisms (SNPs), to conduct population genetic studies on P. falciparum parasites in order to detect signatures of drug selection, migration patterns and genomewide associations.
New approaches for identifying molecular markers of drug resistance were described by a number of speakers. Su described a comprehensive experimental system for analy zing responses of parasites to new drugs and for identifying the genetic determinants of variation. Highthroughput genotyping arrays use a novel molecular inversion probe technology that allows the identification of genetic elements contributing to differential responses to chemi cals or drugs in a wide variety of parasite strains. This system can be used to perform rapid analysis of quanti tative trait loci on the progeny of genetic crosses or parasite isolates collected from the field.
One of us (PH) described how specific mutations under lying chloroquine resistance and artemisinin resistance were identified in a congenic lineage of multidrug resis tant mutants of the rodent malaria Plasmodium chabaudi. Loci associated with drug resistance were mapped using genomewide scans of genetic crosses. Within these loci, mutations in an amino acid transporter (aat1) and a deubiquitinating enzyme (ubp1) were identified by Solexa genome resequencing of mutant and wildtype parasites. Importantly, this approach is rapid. It could, therefore, be used for proactive nomination of candidate resistance genes before resistance to future drugs arises in Plasmodium species that cause disease in humans.
Genomic studies of drug resistance
Central to the meeting was the impressive progress made in the application of single molecule deep sequencing and highdensity genotyping arrays for the investigation of field samples, and their relevance to the discovery and control of drug resistance. Sarah Auburn and Dominic Kwiatkowski (Sanger Institute, Hinxton, UK) described how wholegenome resequencing of clinical parasite iso lates is being used to identify patterns of genome variation in natural Plasmodium populations. They also detailed how challenges associated with sequencing highquality samples directly from the field and resolving mixed infections are being tackled to improve the application of this technology to parasites collected directly from infected people.
Philip Awadalla (University of Montreal, Quebec, Canada) and Sarah Volkman (Harvard School of Public Health, Boston, USA) extended the theme of using genomewide variation data to understand global patterns of P. falciparum parasite diversity. Awadalla has found that highcoverage parasite sequence data suggest a greater extent of diversity than previously anticipated, and described how rare variants could provide insights into malaria evolutionary history, especially for the most recent processes. For instance, regarding the core haplotype around the chloroquineresistance marker gene crt, one can ask whether the rare alleles underlying this variation are the remnant of previous balancing selection or whether they represent the appearance of new resistance variants?
Volkman demonstrated the versatility of highdensity, genomewide genotyping arrays in determining the geographic population structure of the P. faciparum parasite, relationships between linkage disequilibrium and transmission intensity, and the detection of selective sweeps. She described preliminary results from genome wide association studies combining genotyping data with robust drugresistance phenotypes using cultured para sites. This approach detected known loci of resistance to chloroquine and pyrimethamine (crt and dhfr, respec tively) and two putative genes underlying resistance to chloroquine or halofantrine. The genomic studies challenge us to ask how these data and insights regarding genomewide selection, population and evolutionary genetics can serve the publichealth agenda. Since 2002, it has been understood that chloro quine resistance (conferred by crt mutations) arose and spread a limited number of times, producing a selective sweep. Now, extended haplotype analysis suggests that the same is true of multiple mutations in dhfr and dhps, which underlie resistance to the antifolates. One of us (CR) described how microsatellite analysis has defined extended haplotypes around dhfr and dhps in a large number of African field samples. She and her colleagues observe one dominant dhfr triplemutant haplotype of Asian origin throughout Africa. A small number of dhps haplotypes of African origin have strong geographic associations. These data underline the importance of dispersal in the evolution of resistance, and suggest that surveillance for artemisinin resistance in SouthEast Asia and coordinated multi disciplinary containment measures might reduce the local and global spread of resistant parasites. Indeed, this possibility is specified in the ARC3 project.
The genetic architecture of phenotype-genotype relationships
Michael Ferdig (University of Notre Dame, Notre Dame, USA), Su, and Chris Plowe (University of Maryland School of Medicine, Baltimore, USA) all discussed the different possible quantitative relationships between phenotype and genotype. For example, Ferdig addressed the limitations of our (historically necessary) simple 'one geneone pheno type' paradigms headon by pointing out that whereas atovaquone resistance is dramatically bimodal (contingent on one mutation) and chloroquine less so (Figure 1) , we should not assume that the same may be true of responses to other drugs, such as artemisinin. Su showed data exem plifying phenotype distributions for a number of drugs. For instance, both chloroquine and sulfadoxine/pyrimetha mine showed discontinuities in the phenotype distribution, presumably reflecting the effect of one dominant mutation, whereas other drugs such as quinine and dihydro artemisinin showed continuous distributions, perhaps reflecting the small effects of more than one mutation.
Plowe focused our attention onto the consequences of resistance for the disease itself, using the apparently well characterized examples of dhfr and dhps mutations and resistance to antifolate drugs. Although the impact of these mutations on in vitro IC 50 (the concentration of drug showing 50% (of the maximum) inhibition of parasite growth) accumulates gradually, it appears that, in vivo, parasites with all mutations are selected during drug treatment. A different pattern occurs with chloroquine. Crt accounts for only a small part of the variance in chloroquine resistance, yet it appears to be an excellent predictor of clinical resistance. Such data can be used to make predictions regarding drug failure rates and, hence, guide drug use policy.
Immediate questions are: what 'distributions' of artemisinin resistance will be observed, and how will they relate to the current range of variation in Cambodia. And what implications will this have for treatment failure and evolution of resistance in the future?' Abdoulaye Djimde (University of Bamako, Mali) reminded us that to turn research into practical application, we need to go beyond 'the parasite' and 'the genes'. In vivo phenotypes such as quinine sensitivity are a consequence not only of parasite genotype but of other factors, including the age of the patient, their nutritional status, their immune status and their pharmacogenetics. We should expect our understanding of variation to go beyond the genotype of the parasite: optimal strategies will then require holistic, and necessarily complex, approaches.
This resonates with one of the enduring themes of the meeting; the value of multidisciplinary research between genome scientists and malarial biologists in laboratory and field studies. For artemisinin, there is both anxiety and hope. There is growing evidence that parasites with reduced susceptibility are arising in specific foci in South East Asia. On the other hand, multidisciplinary research in the laboratory and the field will optimize treatments, clarify relevant phenotypes, identify and evaluate genetic markers, monitor resistance evolution in time and space and stimulate resistancecontainment practices.
